A new peptide ligand for targeting human carbonic anhydrase IX, identified through the phage display technology

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Askoxylakis, Vasileios ^a   Garcia Boy, Regine ^a   Rana, Shoaib ^a   Krämer, Susanne ^a   Hebling, Ulrike ^a   Mier, Walter ^a   Altmann, Annette ^b   Markert, Annette ^b   Debus, Jürgen ^a   Haberkorn, Uwe ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINYLTHREONYLASPARAGINYLHISTIDYLVALYLPROLYLLEUCYLSERYLPROLYLLYSYLTYROSINE; CARBONATE DEHYDRATASE IX; IODINE 125; MESSENGER RNA; OCTREOTIDE; PEPTIDE; TYROSYLASPARAGINYLTHREONYLASPARAGINYLHISTIDYLVALYLPROLYLLEUCYLSERYLPROLYLLYSYLTYROSINE; UNCLASSIFIED DRUG; CA9 PROTEIN, HUMAN; CARBONATE DEHYDRATASE; LIGAND; PEPTIDE LIBRARY; RECOMBINANT PROTEIN; TUMOR ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING KINETICS; BIOACCUMULATION; BIOPANNING; BLOOD; BRAIN; CELL DENSITY; COLORECTAL CARCINOMA; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG PROTEIN BINDING; DRUG SPECIFICITY; DRUG SYNTHESIS; DRUG TARGETING; DRUG UPTAKE; FEMALE; HEART; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTESTINE; ISOTOPE LABELING; KIDNEY; KIDNEY CARCINOMA; LIGAND BINDING; LIVER; MOUSE; MUSCLE; NONHUMAN; PHAGE DISPLAY; SPLEEN; TISSUE DISTRIBUTION; UMBILICAL VEIN ENDOTHELIAL CELL; ANIMAL; ANOXIA; BAGG ALBINO MOUSE; CHEMISTRY; CYTOLOGY; METHODOLOGY; NUDE MOUSE; RADIOTHERAPY; TUMOR CELL LINE; VASCULAR ENDOTHELIUM;

MUS;

ANIMALS; ANOXIA; ANTIGENS, NEOPLASM; CARBONIC ANHYDRASES; CELL LINE, TUMOR; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; LIGANDS; MICE; MICE, INBRED BALB C; MICE, NUDE; PEPTIDE LIBRARY; PEPTIDES; RADIOTHERAPY; RECOMBINANT PROTEINS;

EID: 79251495097     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015962     Document Type: Article

References (35)

1. Demir R, Naschberger L, Demir I, Melling N, Dimmler A, et al. (2009) Hypoxia generates a more invasive phenotype of tumour cells: An in vivo experimental setup based on the chorioallantoic membrane. Pathol Oncol Res 15: 417-422.
2. Swinson DE, Jones JL, Richardson D, Wykoff C, Turley H, et al. (2003) Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. J Clin Oncol 21: 473-482.
3. Bussink J, Kaanders JH, van der Kogel AJ (2003) Tumor hypoxia at the microregional level: clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers. Radiother Oncol 67: 3-15.
4. Giatromanolaki A, Sivridis E, Kouskoukis C, Gatter KC, Harris AL, et al. (2003) Hypoxia inducible factors 1alpha and 2alpha are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin. Melanoma Res 13: 493-501.
5. Semenza GL (2002) HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med 8(suppl 4): 62-67.
6. Harris AL (2002) Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2: 38-47.
7. Wykoff CC, Beasley NJ, Watson PH, Turner KJ, Pastorek J, et al. (2000) Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 60: 7075-7083.
8. Winum JY, Rami M, Scozzafava A, Montero JL, Supuran C (2008) Carbonic anhydrase IX: a new druggable target for the design of antitumor agents. Med Res Rev 28: 445-463.
9. Niemelä AM, Hynninen P, Mecklin JP, Kuopio T, Kokko A, et al. (2007) Carbonic anhydrase IX is highly expressed in hereditary nonpolyposis colorectal cancer. Cancer Epidemiol Biomarkers Prev 16: 1760-1766.
10. McGuire BB, Fitzpatrick JM (2009) Biomarkers in renal cell carcinoma. Curr Opin Urol 19: 441-446.
11. Kim SJ, Rabbani ZN, Dewhirst MW, Vujaskovic Z, Vollmer RT, et al. (2005) Expression of HIF-1alpha, CA IX, VEGF and MMP-9 in surgically resected non-small cell lung cancer. Lung Cancer 49: 325-335.
12. Haapasalo JA, Nordfors KM, Hilvo M, Rantala IJ, Soini Y, et al. (2006) Expression of carbonic anhydrase IX in astrocytic tumors predicts poor prognosis. Clin Cancer Res 12: 473-477.
13. Skrzypski M, Jassem E, Taron M, Sanchez JJ, Mendez P, et al. (2008) Threegene expression signature predicts survival in early-stage squamous cell carcinoma of the lung. Clin Cancer Res 14: 4794-4799.
14. Mees G, Dierckx R, Vangestel C, Van de Wiele C (2009) Molecular imaging of hypoxia with radiolabelled agents. Eur J Nucl Med Mol Imaging 36: 1674-1686.
15. Raleigh JA, Koch CJ (1990) Importance of thiols in the reductive binding of 2- nitroimidazoles to macromolecules. Biochem Pharmacol 40: 2457-2464.
16. Chrastina A, Závada J Parkkila S Kaluz S, Kaluzova ́ M et al. (2003) Biodistribution and pharmacokinetics of 125I-labeled monoclonal antibody M75 specific for carbonic anhydrase IX, an intrinsic marker of hypoxia, in nude mice xenografted with human colorectal carcinoma. Int J Cancer 105: 873-881.
17. Ahlskog JK, Schliemann C, Ma rlind J, Qureshi U, Ammar A, et al. (2009) Human monoclonal antibodies targeting carbonic anhydrase IX for the molecular imaging of hypoxic regions in solid tumours. Br J Cancer 101: 645-657.
18. Brouwers AH, Buijs WC, Mulders PF, de Mulder PH, van den Broek WJ, et al. (2005) Radioimmunotherapy with [131I]cG250 in patients with metastasized renal cell cancer: dosimetric analysis and immunologic response. Clin Cancer es 11: 7178-7186.
19. Brissette R, Prendergast JK, Goldstein NI (2006) Identification of cancer targets nd therapeutics using phage display. Curr Opin Drug Discov Devel 9: 63-369.
20. Pasqualini R, Ruoslahti E (1996) Organ targeting in vivo using phage display eptide libraries. Nature 380: 364-366.
21. Askoxylakis V, Zitzmann S, Mier W, Graham K, Krämer S et al. (2005) Preclinical evaluation of the breast cancer cell-binding peptide, p160. Clin Cancer Res 11: 6705-6712.
22. Crim JW, Garczynski SF, Brown MR (2002) Approaches to radioiodination of insect neuropeptides. Peptides 23: 2045-2051.
23. Rofstad EK, Sundfør K, Lyng H, Tropé CG (2000) Hypoxia-induced treatment failure in advanced squamous cell carcinoma of the uterine cervix is primarily due to hypoxia-induced radiation resistance rather than hypoxia-induced metastasis. Br J Cancer 83: 354-359.
24. Jubb AM, Pham TQ, Hanby AM, Frantz GD, Peale FV, et al. (2004) Expression of vascular endothelial growth factor, hypoxia inducible factor 1alpha, and carbonic anhydrase IX in human tumours. J Clin Pathol 57: 504-512.
25. Krause BJ, Beck R, Souvatzoglou M, Piert M (2006) PET and PET/CT studies of tumor tissue oxygenation. Q J Nucl Med Mol Imaging 50: 28-43.
26. Zimny M, Gagel B, DiMartino E, Hamacher K, Coenen HH, et al. (2006) FDG-a marker of tumour hypoxia? A comparison with [18F]fluoromisonidazole and pO2-polarography in metastatic head and neck cancer. Eur J Nucl Med Mol Imaging 33: 1426-1431.
27. Thorwarth D, Eschmann SM, Holzner F, Paulsen F, Alber M (2006) Combined uptake of [18F]FDG and [18F]FMISO correlates with radiation therapy outcome in head-and-neck cancer patients. Radiother Oncol 80: 151-156.
28. Hulikova A, Zatovicova M, Svastova E, Ditte P, Brasseur R, et al. (2009) Intact ntracellular tail is critical for proper functioning of the tumor-associated, ypoxia regulated carbonic anhydrase IX. FEBS Lett 583: 3563-3568.
29. Li G, Passebosc-Faure K, Lambert C, Gentil-Perret A, Blanc F, et al. (2001) The xpression of G250/mn/CA9 antigen by flow cytometry: its possible implication or detection of micrometastatic renal cancer cells. Clin Cancer Res 7: 89-92.
30. Bakker WH, Krenning EP, Breeman WA, Koper JW, Kooij PP, et al. (1990) eceptor scintigraphy with a radioiodinated somatostatin analogue: Radiolabeling, urification, biologic activity, and in vivo application in animals. J Nucl Med 31: 1501-1509.
31. Sun X, Chu T, Liu X, Wang X (2006) t-Butyloxycarbonyl: An ordinary but romising group for protecting peptides from deiodination. Appl Radiat Isot 64: 45-650.
32. Mier W, Zitzmann S, Krämer S, Reed J, Knapp EM, et al. (2007) Influence of helate conjugation on a newly identified tumor-targeting peptide. J Nucl Med 8: 1545-1552.
33. Askoxylakis V, Mier W, Zitzmann S, Ehemann V, Zhang J, et al. (2006) haracterization and development of a peptide (p160) with affinity for euroblastoma cells. J Nucl Med 47: 981-988.
34. Lee SH, Lee S, Youn YS, Na DH, Chae SY, et al. (2005) Synthesis, haracterization, and pharmacokinetic studies of PEGylated glucagon-like eptide-1. Bioconjug Chem 16: 377-382.
35. Boy RG, Mier W, Nothelfer EM, Altmann A, Eisenhut M, et al. (2010) unflower trypsin inhibitor 1 derivatives as molecular scaffolds for the evelopment of novel peptidic radiopharmaceuticals. Mol Imaging Biol 12: 77-385.